 |
|
Effects of Cigarette Smoking on Spatial Working Memory and Attentional Deficits in Schizophrenia
Involvement of Nicotinic Receptor Mechanisms
Kristi A. Sacco, PsyD;
Angelo Termine, BS;
Aisha Seyal, BS;
Melissa M. Dudas, BS;
Jennifer C. Vessicchio, LCSW;
Suchitra Krishnan-Sarin, PhD;
Peter I. Jatlow, MD;
Bruce E. Wexler, MD;
Tony P. George, MD
Arch Gen Psychiatry. 2005;62:649-659.
Background Cigarette smoking rates in schizophrenia are higher than in the general population.
Objectives To determine whether cigarette smoking modifies cognitive deficits in schizophrenia and to establish the role of nicotinic acetylcholine receptors (nAChRs) in mediating cigarette smoking–related cognitive enhancement.
Design Neuropsychological assessments were performed at smoking baseline, after overnight abstinence, and after smoking reinstatement across 3 separate test weeks during which subjects were pretreated in a counterbalanced manner with the nonselective nAChR antagonist mecamylamine hydrochloride (0, 5, or 10 mg/d).
Participants Twenty-five smokers with schizophrenia and 25 control smokers.
Setting Outpatient mental health center.
Main Outcome Measures Visuospatial working memory (VSWM) and Continuous Performance Test (CPT) scores.
Results In smokers with schizophrenia and control smokers, overnight abstinence led to undetectable plasma nicotine levels and an increase in tobacco craving. While abstinence reduced CPT hit rate in both groups, VSWM was only impaired in smokers with schizophrenia. Smoking reinstatement reversed abstinence-induced cognitive impairment. Enhancement of VSWM and CPT performance by smoking reinstatement in smokers with schizophrenia, but not the subjective effects of smoking, was blocked by mecamylamine treatment.
Conclusions Cigarette smoking may selectively enhance VSWM and attentional deficits in smokers with schizophrenia, which may depend on nAChR stimulation. These findings may have implications for understanding the high rates of smoking in schizophrenia and for developing pharmacotherapies for cognitive deficits and nicotine dependence in schizophrenia.
Author Affiliations: Program for Research in Smokers with Mental Illness (PRISM) (Drs Sacco and George; Mr Termine; and Mss Seyal, Dudas, and Vessicchio), Division of Substance Abuse (Dr Krishnan-Sarin), Department of Psychiatry (Drs Sacco, Wexler, and George), Department of Laboratory Medicine (Dr Jatlow), Yale University School of Medicine, New Haven, Conn.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
Freedman et al.
Am. J. Psychiatry 2008;165:1040-1047.
ABSTRACT
| FULL TEXT
Schizophrenia, Psychiatric Genetics, and Darwinian Psychiatry: An Evolutionary Framework
Pearlson and Folley
Schizophr Bull 2008;34:722-733.
ABSTRACT
| FULL TEXT
{alpha}7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1
Mathew et al.
Hum Mol Genet 2007;16:2921-2932.
ABSTRACT
| FULL TEXT
Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia
Gray and Roth
Schizophr Bull 2007;33:1100-1119.
ABSTRACT
| FULL TEXT
Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia
Buchanan et al.
Schizophr Bull 2007;33:1120-1130.
ABSTRACT
| FULL TEXT
Elevations of Endogenous Kynurenic Acid Produce Spatial Working Memory Deficits
Chess et al.
Schizophr Bull 2007;33:797-804.
ABSTRACT
| FULL TEXT
Successful Tobacco Dependence Treatment in Schizophrenia
Williams and Foulds
Am. J. Psychiatry 2007;164:222-227.
FULL TEXT
Why Do So Many Patients with Schizophrenia Smoke?
JWatch Psychiatry 2005;2005:7-7.
FULL TEXT
|
